Glimepiride Viatris (Glimepiride)

Glimepiride Viatris is indicated for the management of hyperglycemia in adults diagnosed with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• Monotherapy for patients whose glycemic control is insufficient with lifestyle measures alone.
• Combination therapy with other oral antidiabetic agents such as metformin when a single drug does not achieve target glucose levels.
• Use in patients with stable renal function where sulfonylurea therapy is appropriate.
• Adjunct to insulin therapy in selected cases to reduce insulin dose requirements.
• Off‑label use in research settings only, following ethical approval.

The safety profile of glimepiride includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common

• Mild to moderate hypoglycemia, which may present as shakiness, sweating, or hunger when meals are delayed or carbohydrate intake is low.
• Gradual weight gain, often modest, associated with increased insulin secretion.
• Nausea, occasional abdominal discomfort, or dyspepsia.
• Transient headache, dizziness, or visual disturbances.

Serious

• Severe hypoglycemia that can cause loss of consciousness, seizures, or require emergency medical assistance.
• Allergic reactions ranging from skin rash and pruritus to angio‑edema and, rarely, anaphylaxis.
• Liver injury indicated by marked elevations in transaminases or clinical hepatitis.

Before initiating Glimepiride Viatris, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Avoid use in patients with a history of severe hypoglycemia or sulfonylurea allergy.
• Caution in elderly patients, who may be more susceptible to hypoglycemia.
• Pregnancy and lactation status should be reviewed, as safety data are limited.
• Monitor blood glucose regularly, especially when initiating therapy or changing dose.
• Educate patients on recognizing and managing hypoglycemia symptoms.
• Consider cardiovascular status, as sulfonylureas may affect cardiac ischemic preconditioning.

Glimepiride Viatris can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride plasma levels.
• Beta‑blockers that may mask hypoglycemia symptoms.

Use with caution

• Concurrent insulin or insulin secretagogues; dose adjustments and glucose monitoring are required.
• Thiazide diuretics, which may increase blood glucose and counteract glimepiride’s effect.
• Macrolide antibiotics (e.g., erythromycin) that can modestly increase glimepiride concentrations.
• Antidepressants such as SSRIs, which may affect glycemic control.